<DOC>
	<DOCNO>NCT01456585</DOCNO>
	<brief_summary>This pilot study evaluate role addition CP870 , 893 neoadjuvant adjuvant setting patient resectable pancreatic cancer . Patients receive standard surgery follow chemoradiation disease , one dose gem/cp 870,893 pre-op 3 dos post-op .</brief_summary>
	<brief_title>Phase 1 Study Preoperative Gemcitabine Plus CP-870 , 893 Followed Addition CP-870,893 Standard -Of-care Adjuvant Chemoradiation Patients With Newly Diagnosed Resectable Pancreatic Carcinoma</brief_title>
	<detailed_description>This open-label single-arm , phase 1 , trial . Ten patient newly diagnose resectable pancreatic carcinoma receive gemcitabine CP-870,893 two week prior surgical resection subsequently standard-of-care adjuvant chemoradiation therapy ( time CP-870,893 give day 3 three 28-day cycle gemcitabine ) . Previously establish dos agent use give IV infusion .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histological documentation primary adenocarcinoma pancreas Surgically eligible tumor resection curative intent Age &gt; 18 year old ECOG PS 0 1 Adequate bone marrow function ( WBC &gt; 3,000 ; Hgb &gt; 9 ; Plt &gt; 100 ) Adequate renal function ( Cr &lt; 1.5ULN ) Adequate hepatic function ( total bilirubin WNL unless associate hepatobiliary metastasis Gilbert syndrome , total bilirubin &lt; 2x ULN ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x ULN Signed , write informed consent Non ductal adenocarcinoma , neuroendocrine neoplasm , cystic tumor pancreas cystadenomas , cystadenocarcinomas solid pseudopapillary neoplasm . In addition adenocarcinoma arise duodenum , distal bile duct , ampulla also exclude . Patients M1 disease . Patients type recurrent pancreatic adenocarcinoma Prior therapy chemotherapy radiation therapy pancreatic cancer Patients previous history active malignancy within 5 year prior study entry , except 1 ) situ cervical carcinoma 2 ) nonmelanoma skin cancer Previous treatment compound target CD40 Concurrent treatment anticancer agent outside protocol . Prior allogeneic bone marrow transplant History autoimmune disorder , include type 1 diabetes mellitus , pemphigus vulgaris , systemic mastocytosis , systemic lupus erythromatosis , dermatomyositis/polymyositis , rheumatoid arthritis , systemic sclerosis , Sjorgen 's syndrome , vasculitis/arteritis , Behcet 's syndrome , autoimmune thyroiditis , multiple sclerosis , uveitis . Vitiligo allow . History ( within previous year ) stroke transient ischemic attack , unstable angina , myocardial infarction , congestive heart failure . History deep venous thrombosis migratory thrombophlebitis ( Trousseau ) ; Hereditary acquire coagulopathies ( e.g. , hemophilia , von Willebrands 's disease , cancerassociated DIC ) Prior allergic reaction attribute monoclonal antibody . Concurrent plan concurrent treatment systemic high dose ( immunosuppressive ) corticosteroid treatment systemic corticosteroid within 4 week baseline . Treatment another therapeutic clinical trial within 4 week enrollment trial . Concurrent plan concurrent treatment anticoagulant Coumadin heparin , except maintain patency indwell catheter . Ongoing active infection ; treatment systemic antibiotic antifungal ongoing recurrent infection ( topical use antibiotic antifungal allow ) Pregnancy breastfeedingfemale patient must surgically sterile , postmenopausal , must agree use effective contraception period therapy 12 month follow last dose CP870,893 . All female patient reproductive potential may participate unless agree use effective contraceptive method . Other uncontrolled , concurrent illness would preclude study participation ; , psychiatric illness social challenge would entail unreasonable risk preclude inform consent compliance study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Histological documentation</keyword>
	<keyword>primary adenocarcinoma pancreas</keyword>
	<keyword>surgically eligible</keyword>
	<keyword>tumor resection</keyword>
	<keyword>curative intent</keyword>
</DOC>